Alpine Immune Sciences (Alpine Immune Sciences) Accounts Receivable : $0.17 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Alpine Immune Sciences's accounts receivables for the quarter that ended in Dec. 2023 was $0.17 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Alpine Immune Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 0.49.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Alpine Immune Sciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $4.57.

Alpine Immune Sciences Accounts Receivable Historical Data

The historical data trend for Alpine Immune Sciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Accounts Receivable Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

25.00

0.39

0.17

Alpine Immune Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															0.39	0.67	0.28	0.22	0.17

Alpine Immune Sciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Alpine Immune Sciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Alpine Immune Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.167	/	30.853	*	91
=	0.49

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Alpine Immune Sciences's accounts receivable are only considered to be worth 75% of book value:

Alpine Immune Sciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(327.412	+	0.75 * 0.167	+	0.5 * 0	-	51.911
-	0	-	0)	/	60.3475
=	4.57

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Alpine Immune Sciences Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (Alpine Immune Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (NAS:ALPN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

34LA:Germany

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Executives

Mitchell Gold	director, officer: Executive Chairman and CEO	ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James Paul Rickey	officer: Senior VP and CFO	ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Xiangmin Cui	director, 10 percent owner	NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Remy Durand	officer: Chief Business Officer	C/O ALPINE IMMUNE SCIENCES, INC., 185 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98012
Jorn Drappa	director	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Andrew Seth Sandler	officer: Chief Medical Officer	1301 2ND AVE, SEATTLE WA 98101
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
Christopher Peetz	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Decheng Capital China Life Sciences Usd Fund Iii, L.p.	10 percent owner	UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
Alpine Immunosciences, L.p.	10 percent owner	600 STEWART STREET, SUITE 1503, SEATTLE WA 98101
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022